| |
| |
|
| Insider
Information: |
Ando Dale G |
| Relationship: |
VP, Therapeutic Dev. &... |
| City: |
South San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
107,328 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$56,240 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
107,328 |
|
|
| Total
Value |
$56,240 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Sangamo Biosciences Inc |
SGMO |
VP, Therapeutic Dev. &... |
2015-12-12 |
107,328 |
2011-12-08 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
80 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2013-04-26 |
4 |
AS |
$10.72 |
$160,746 |
D/D |
(15,000) |
88,798 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2013-05-28 |
4 |
OE |
$3.61 |
$54,150 |
D/D |
15,000 |
103,798 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2013-05-28 |
4 |
AS |
$8.32 |
$124,818 |
D/D |
(15,000) |
88,798 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2013-07-26 |
4 |
AS |
$10.08 |
$151,308 |
D/D |
(15,000) |
86,798 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2013-07-26 |
4 |
OE |
$3.45 |
$49,930 |
D/D |
13,000 |
90,798 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2013-08-26 |
4 |
OE |
$3.45 |
$49,930 |
D/D |
13,000 |
88,798 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2013-08-26 |
4 |
AS |
$10.04 |
$150,606 |
D/D |
(15,000) |
84,798 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2013-09-26 |
4 |
OE |
$3.45 |
$58,570 |
D/D |
15,000 |
87,798 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2013-09-26 |
4 |
AS |
$10.56 |
$158,574 |
D/D |
(15,000) |
84,798 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2013-10-28 |
4 |
AS |
$10.39 |
$155,780 |
D/D |
(15,000) |
86,798 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2013-10-28 |
4 |
OE |
$3.45 |
$58,570 |
D/D |
15,000 |
89,798 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2013-11-26 |
4 |
OE |
$3.45 |
$58,570 |
D/D |
15,000 |
91,798 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2013-11-26 |
4 |
AS |
$11.83 |
$177,378 |
D/D |
(15,000) |
88,798 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2013-12-12 |
4 |
D |
$12.12 |
$179,170 |
D/D |
(14,783) |
97,015 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2013-12-12 |
4 |
A |
$0.00 |
$0 |
D/D |
23,000 |
111,798 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2013-12-26 |
4 |
OE |
$3.45 |
$55,230 |
D/D |
15,000 |
99,015 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2013-12-26 |
4 |
AS |
$14.22 |
$215,477 |
D/D |
(15,000) |
97,015 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2014-01-27 |
4 |
OE |
$3.45 |
$55,230 |
D/D |
15,000 |
99,015 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2014-01-27 |
4 |
AS |
$18.56 |
$278,729 |
D/D |
(15,000) |
97,015 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2014-02-26 |
4 |
AS |
$19.72 |
$295,752 |
D/D |
(15,000) |
97,015 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2014-02-26 |
4 |
OE |
$3.45 |
$55,230 |
D/D |
15,000 |
99,015 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2014-03-26 |
4 |
OE |
$3.45 |
$55,230 |
D/D |
15,000 |
99,015 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2014-03-26 |
4 |
AS |
$18.64 |
$279,695 |
D/D |
(15,000) |
97,015 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2014-04-28 |
4 |
S |
$13.63 |
$204,532 |
D/D |
(15,000) |
97,015 |
0 |
- |
|
| SGMO |
Sangamo Biosciences Inc |
VP, Therapeutic Dev. & CMO |
• – – |
2014-04-28 |
4 |
OE |
$3.45 |
$55,230 |
D/D |
15,000 |
99,015 |
0 |
- |
|
80 Records found
|
|
Page 2 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
